Evotec SE (EVO)
| Market Cap | 994.57M |
| Revenue (ttm) | 859.03M |
| Net Income (ttm) | -223.54M |
| Shares Out | 177.56M |
| EPS (ttm) | -1.26 |
| PE Ratio | n/a |
| Forward PE | 120.12 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 17,286 |
| Open | 2.740 |
| Previous Close | 2.710 |
| Day's Range | 2.740 - 2.790 |
| 52-Week Range | 2.308 - 4.415 |
| Beta | 1.30 |
| Analysts | Buy |
| Price Target | 5.12 (+86.86%) |
| Earnings Date | Aug 12, 2026 |
About EVO
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and c... [Read more]
Financial Performance
In 2025, Evotec SE's revenue was 788.37 million, a decrease of -1.08% compared to the previous year's 796.97 million. Losses were -103.52 million, -47.21% less than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for EVO stock is "Buy." The 12-month stock price target is $5.12, which is an increase of 86.86% from the latest price.
News
Evotec SE Proxy statement: Proxy filing
Evotec SE filed a proxy statement on June 23, 2026, providing details for shareholder voting and corporate governance matters.
Evotec SE Slides: Company presentation
Evotec SE has posted slides in relation to its latest quarterly earnings report, which was published on June 17, 2026.
Evotec Reports Results of the Annual General Meeting 2026
11.06.2026 / 15:30 CET/CESTThe issuer is solely responsible for the content of this announcement. All agenda items adopted Dieter Weinand and Dr. Wolfgang Hofmann newly elected to the Supervisory Boar...
Evotec SE: Evotec Appoints Rui Wang as Head of Global In Silico and AI
HAMBURG, DE / ACCESS Newswire / June 2, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced the appointment of Rui Wang as Executive Vice President, Head of Global In Silico...
Evotec Appoints Rui Wang as Head of Global In Silico and AI
HAMBURG, DE / ACCESS Newswire / June 2, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced the appointment of Rui Wang as Executive Vice President, Head of Global In Silico an...
EQS-NVR: Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Total Voting Rights Announcement: Evotec SE / Total Voting Rights Announcement Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Euro...
Evotec SE Successfully Placed €116.1 Million Convertible Bonds
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH, OR TO PERSONS IN ANY JURISDICTION TO...
Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall
Joint Evotec-Almirall team advances small molecule program to preclinical development significantly outperforming standard industry timelines Collaboration leverages Evotec's end-to-end integrated AI/...
Evotec Receives Grants to Advance Tuberculosis Treatment
Grants support discovery and development of novel drug candidates and evaluation and prioritization of advanced drug regimens for clinical testing New funding from the Gates Foundation extends Evotec'...
Evotec Announces New Nomination to Board of Directors
Nomination of Dr. Wolfgang Hofmann as independent Supervisory Board member to further strengthen oversight and governance capabilities Conclusion of cooperation agreement with MAK Capital following co...
Evotec SE to Announce First Quarter 2026 Results on May 6, 2026
HAMBURG, DE / ACCESS Newswire / April 29, 2026 / Evotec SE (NASDAQ:EVO; Frankfurt Prime Standard: EVT) will hold a webcast and conference call to announce its financial results for the first quarter 2...
Evotec Announces Chief Financial Officer Transition
Paul Hitchin to step down as of April 30, 2026 Claire Hinshelwood appointed to CFO role as of May 1, 2026 HAMBURG, DE / ACCESS Newswire / April 24, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standa...
Evotec Appoints Dr. Ingrid Müller as Chief Operating Officer
Will play key role in strengthening cross-functional execution in support of global platform, scientific capabilities and partner delivery as well as the execution of the Horizon initiative Brings mor...
Evotec vows to further engage with investor MAK, who demanded change
Evotec said on Tuesday it would continue a dialogue with investor MAK Capital, which has published a list of changes it wants the German biotech firm to make.
Evotec Nominates Dieter Weinand as Supervisory Board Chairman
Strengthens Supervisory Board leadership to support Evotec's transformation, with a focus on commercial execution, strategic partnerships and profitability Industry veteran brings more than 30 years o...
Evotec SE to Announce Fourth Quarter and Full-Year 2025 Results on April 8, 2026
HAMBURG, DE / ACCESS Newswire / April 1, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) will hold a webcast and conference call to announce its financial results for the fourth quarter an...
Evotec Appoints Dr. Ashiq H. Khan as Chief Commercial Officer
HAMBURG, DE / ACCESS Newswire / April 1, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced the appointment of Dr. Ashiq H. Khan as EVP Global Head, Chief Commercial Officer.
Just - Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses
The program leverages Just - Evotec Biologics' advanced biomanufacturing platform to deliver high-quality, scalable, cost-efficient production through significantly higher yields Manufacturing process...
Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation
Dosing of first patient initiates Phase 1 clinical evaluation of BMS-986506 for the treatment of advanced clear cell renal cell carcinoma, the most common form of kidney cancer Transformative moment i...
Evotec Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, March 11, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Evotec SE (NASDAQ: EVO). The investigation focuses on Evotec executive of...
Just - Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access
Just - Evotec Biologics will optimize monoclonal antibodies ("mAbs") and other biologic modalities Investment enables ten new J.MD™ projects encompassing molecular optimization including, but not limi...
Evotec Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations
Creation of new Executive Vice President role integrating Global Communications and Investor Relations to strengthen strategic messaging and stakeholder alignment HAMBURG, DE / ACCESS Newswire / Janua...
Evotec Closes Sale of Just - Evotec Biologics' Toulouse Site to Sandoz
All closing requirements satisfied following announcement of a non-binding term-sheet agreement in July and signing of contract in November Agreement includes approximately US$ 350 m in cash for Just ...
Evotec-Partner Bayer Starts Phase 2 Study for Treatment of Patients with Alport Syndrome
Phase 2 clinical trial initiated to evaluate SEMA3A mAb as potential treatment for Alport syndrome Milestone payment to Evotec expected upon first dosing of first study participant in early 2026 HAMBU...
Evotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation Partnership
Milestone payment reflects continued progress under strategic research collaboration addressing high-need patient populations FDA clearance of IND application triggered a US$ 5 m milestone payment to ...